


Figure S6



Supplemental Figure 6. Combination of MEK and ERK inhibitors in *BRAF* mutant cell lines. (a) Colo205 (*BRAF*^{V600E}, colorectal) or (b) A375 (*BRAF*^{V600E}, melanoma) cells were treated with DMSO, cobimetinib, GDC-0994 or the combination at the indicated concentrations for 24 hr followed by analysis of pathway activation at the level of p90RSK, cyclin D1, p27, and cleaved PARP relative to the loading control GAPDH. (c) Cell death was measured after 48 hr post treatment (NucELISA) at the indicated concentrations. One-way ANOVA, **** p<0.001. (d) Colo205 or (e) A375 cells were treated with single agent cobimetinib, GDC-0994 or the combination at the indicated fixed ratio concentrations and cell viability was measured after 72 hr in culture (CellTiter-Glo®).